
    
      MT1002 is a novel bispecific peptide with properties of a direct thrombin inhibitor and a
      glycoprotein IIb/IIIa inhibitor.

      Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve
      target ACT.
    
  